Related Experiment Videos
In vitro activity of FK-037. A parenteral cephalosporin
J Segreti1, J Kraatz, M Goldman
1Department of Internal Medicine, Rush Medical College, Chicago, Illinois 60612.
Abstract:
The in vitro activity of FK-037, a new extended spectrum cephalosporin, was determined against 398 recent clinical isolates consisting of ceftazidime-susceptible and -resistant, aerobic Gram-negative rods, penicillin-susceptible and resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-susceptible S. aureus, methicillin-susceptible coagulase-negative staphylococci, and methicillin-resistant coagulase-negative staphylococci. Comparative drugs included ceftazidime, imipenem, and amikacin. Susceptibility testing was performed using a broth microdilution method. FK-037 showed greater activity than ceftazidime against ceftazidime-susceptible, aerobic Gram-negative rods. FK-037 showed enhanced activity compared with ceftazidime against Gram-positive organisms, including penicillin-resistant S. pneumoniae. Mutational frequencies for representative Gram-negative rods were comparable for FK-037 and ceftazidime.
Insights
FK-037, a novel extended-spectrum cephalosporin, demonstrates superior in vitro activity against Gram-negative rods and Gram-positive organisms, including resistant strains. Its efficacy rivals ceftazidime, offering a promising new antibiotic option.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Extended-spectrum cephalosporins are crucial in treating bacterial infections.
- Emergence of antibiotic resistance necessitates development of new antimicrobial agents.
- FK-037 represents a new generation cephalosporin with potential for broader activity.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of FK-037.
- To compare FK-037's efficacy against ceftazidime, imipenem, and amikacin.
- To assess FK-037's activity against a diverse range of clinical isolates, including resistant strains.
Main Methods:
- Broth microdilution method used for susceptibility testing.
- Tested against 398 recent clinical isolates.
- Isolates included aerobic Gram-negative rods, Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible and resistant).
Main Results:
- FK-037 exhibited greater in vitro activity than ceftazidime against ceftazidime-susceptible aerobic Gram-negative rods.
- FK-037 demonstrated enhanced activity compared to ceftazidime against Gram-positive organisms, including penicillin-resistant S. pneumoniae.
- Mutational frequencies for Gram-negative rods were comparable between FK-037 and ceftazidime.
Conclusions:
- FK-037 possesses significant in vitro activity against a wide spectrum of clinically relevant bacteria.
- The new cephalosporin shows promise as an alternative or successor to existing agents, particularly against resistant pathogens.
- Further clinical investigation is warranted to confirm FK-037's therapeutic potential.